Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

RKDA vs LIN vs APD vs PGEN

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
RKDA
Arcadia Biosciences, Inc.

Agricultural Inputs

Basic MaterialsNASDAQ • US
Market Cap$2M
5Y Perf.-99.2%
LIN
Linde plc

Chemicals - Specialty

Basic MaterialsNASDAQ • GB
Market Cap$228.85B
5Y Perf.+144.1%
APD
Air Products and Chemicals, Inc.

Chemicals - Specialty

Basic MaterialsNYSE • US
Market Cap$65.68B
5Y Perf.+22.1%
PGEN
Precigen, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.22B
5Y Perf.+88.6%

RKDA vs LIN vs APD vs PGEN — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
RKDA logoRKDA
LIN logoLIN
APD logoAPD
PGEN logoPGEN
IndustryAgricultural InputsChemicals - SpecialtyChemicals - SpecialtyBiotechnology
Market Cap$2M$228.85B$65.68B$1.22B
Revenue (TTM)$5M$34.66B$12.46B$6M
Net Income (TTM)$-2M$7.13B$2.11B$-247M
Gross Margin36.2%46.0%32.0%23.0%
Operating Margin-51.4%28.8%18.4%-18.6%
Forward P/E27.7x22.5x
Total Debt$0.00$26.99B$18.41B$6M
Cash & Equiv.$259K$5.06B$1.86B$30M

RKDA vs LIN vs APD vs PGENLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

RKDA
LIN
APD
PGEN
StockMay 20May 26Return
Arcadia Biosciences… (RKDA)1000.8-99.2%
Linde plc (LIN)100244.1+144.1%
Air Products and Ch… (APD)100122.1+22.1%
Precigen, Inc. (PGEN)100188.6+88.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: RKDA vs LIN vs APD vs PGEN

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: LIN leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Air Products and Chemicals, Inc. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. PGEN also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
RKDA
Arcadia Biosciences, Inc.
The Secondary Option

RKDA lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: basic materials exposure
LIN
Linde plc
The Growth Play

LIN carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 3.0%, EPS growth 7.1%, 3Y rev CAGR 0.6%
  • 375.2% 10Y total return vs APD's 166.4%
  • Lower volatility, beta 0.24, Low D/E 67.9%, current ratio 0.88x
  • 3.0% revenue growth vs PGEN's -36.9%
Best for: growth exposure and long-term compounding
APD
Air Products and Chemicals, Inc.
The Income Pick

APD is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.

  • Dividend streak 29 yrs, beta 0.45, yield 2.4%
  • Beta 0.45, yield 2.4%, current ratio 1.38x
  • Better valuation composite
  • 2.4% yield, 29-year raise streak, vs LIN's 1.2%, (2 stocks pay no dividend)
Best for: income & stability and defensive
PGEN
Precigen, Inc.
The Momentum Pick

PGEN is the clearest fit if your priority is momentum.

  • +207.4% vs RKDA's -74.4%
Best for: momentum
See the full category breakdown
CategoryWinnerWhy
GrowthLIN logoLIN3.0% revenue growth vs PGEN's -36.9%
ValueAPD logoAPDBetter valuation composite
Quality / MarginsLIN logoLIN20.6% margin vs PGEN's -39.1%
Stability / SafetyLIN logoLINBeta 0.24 vs PGEN's 1.44
DividendsAPD logoAPD2.4% yield, 29-year raise streak, vs LIN's 1.2%, (2 stocks pay no dividend)
Momentum (1Y)PGEN logoPGEN+207.4% vs RKDA's -74.4%
Efficiency (ROA)LIN logoLIN8.3% ROA vs PGEN's -144.1%, ROIC 11.3% vs -152.8%

RKDA vs LIN vs APD vs PGEN — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

RKDAArcadia Biosciences, Inc.
FY 2025
Product
100.0%$5M
LINLinde plc
FY 2025
Americas Segment
45.9%$15.2B
EMEA Segment
25.8%$8.5B
APAC Segment
20.1%$6.7B
Engineering Segment
8.2%$2.7B
APDAir Products and Chemicals, Inc.
FY 2025
On-site
51.3%$6.2B
Merchant
44.3%$5.3B
Sale of Equipment
4.3%$520M
PGENPrecigen, Inc.
FY 2024
Exemplar Segment
100.0%$4M

RKDA vs LIN vs APD vs PGEN — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLINLAGGINGRKDA

Income & Cash Flow (Last 12 Months)

LIN leads this category, winning 4 of 6 comparable metrics.

LIN is the larger business by revenue, generating $34.7B annually — 7133.6x RKDA's $5M. LIN is the more profitable business, keeping 20.6% of every revenue dollar as net income compared to PGEN's -39.1%. On growth, PGEN holds the edge at +2.1% YoY revenue growth, suggesting stronger near-term business momentum.

MetricRKDA logoRKDAArcadia Bioscienc…LIN logoLINLinde plcAPD logoAPDAir Products and …PGEN logoPGENPrecigen, Inc.
RevenueTrailing 12 months$5M$34.7B$12.5B$6M
EBITDAEarnings before interest/tax-$2M$12.1B$3.9B-$115M
Net IncomeAfter-tax profit-$2M$7.1B$2.1B-$247M
Free Cash FlowCash after capex-$5M$5.1B$1.1B-$76M
Gross MarginGross profit ÷ Revenue+36.2%+46.0%+32.0%+23.0%
Operating MarginEBIT ÷ Revenue-51.4%+28.8%+18.4%-18.6%
Net MarginNet income ÷ Revenue-48.1%+20.6%+16.9%-39.1%
FCF MarginFCF ÷ Revenue-97.6%+14.7%+8.9%-12.0%
Rev. Growth (YoY)Latest quarter vs prior year-25.9%+8.2%+8.8%+2.1%
EPS Growth (YoY)Latest quarter vs prior year+16.9%+13.4%+141.1%-11.7%
LIN leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

Evenly matched — RKDA and APD each lead in 2 of 5 comparable metrics.

On an enterprise value basis, LIN's 19.7x EV/EBITDA is more attractive than APD's 119.7x.

MetricRKDA logoRKDAArcadia Bioscienc…LIN logoLINLinde plcAPD logoAPDAir Products and …PGEN logoPGENPrecigen, Inc.
Market CapShares × price$2M$228.8B$65.7B$1.2B
Enterprise ValueMkt cap + debt − cash$1M$250.8B$82.2B$1.2B
Trailing P/EPrice ÷ TTM EPS-0.64x33.85x-166.67x-8.83x
Forward P/EPrice ÷ next-FY EPS est.27.67x22.46x
PEG RatioP/E ÷ EPS growth rate1.33x
EV / EBITDAEnterprise value multiple19.75x119.66x
Price / SalesMarket cap ÷ Revenue0.31x6.73x5.46x309.66x
Price / BookPrice ÷ Book value/share0.36x5.82x3.79x28.85x
Price / FCFMarket cap ÷ FCF44.97x
Evenly matched — RKDA and APD each lead in 2 of 5 comparable metrics.

Profitability & Efficiency

LIN leads this category, winning 6 of 9 comparable metrics.

LIN delivers a 17.8% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-6 for PGEN. PGEN carries lower financial leverage with a 0.14x debt-to-equity ratio, signaling a more conservative balance sheet compared to APD's 1.06x. On the Piotroski fundamental quality scale (0–9), LIN scores 6/9 vs APD's 2/9, reflecting solid financial health.

MetricRKDA logoRKDAArcadia Bioscienc…LIN logoLINLinde plcAPD logoAPDAir Products and …PGEN logoPGENPrecigen, Inc.
ROE (TTM)Return on equity-40.6%+17.8%+11.9%-5.9%
ROA (TTM)Return on assets-26.1%+8.3%+5.1%-144.1%
ROICReturn on invested capital-2.5%+11.3%-2.0%-152.8%
ROCEReturn on capital employed-129.5%+13.0%-2.4%-107.2%
Piotroski ScoreFundamental quality 0–92623
Debt / EquityFinancial leverage0.68x1.06x0.14x
Net DebtTotal debt minus cash-$259,000$21.9B$16.6B-$24M
Cash & Equiv.Liquid assets$259,000$5.1B$1.9B$30M
Total DebtShort + long-term debt$0$27.0B$18.4B$6M
Interest CoverageEBIT ÷ Interest expense34.52x12.00x-273.83x
LIN leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

PGEN leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in LIN five years ago would be worth $17,394 today (with dividends reinvested), compared to $106 for RKDA. Over the past 12 months, PGEN leads with a +207.4% total return vs RKDA's -74.4%. The 3-year compound annual growth rate (CAGR) favors PGEN at 49.2% vs RKDA's -44.4% — a key indicator of consistent wealth creation.

MetricRKDA logoRKDAArcadia Bioscienc…LIN logoLINLinde plcAPD logoAPDAir Products and …PGEN logoPGENPrecigen, Inc.
YTD ReturnYear-to-date-48.8%+15.5%+19.2%-3.0%
1-Year ReturnPast 12 months-74.4%+11.2%+14.2%+207.4%
3-Year ReturnCumulative with dividends-82.8%+39.7%+7.0%+232.0%
5-Year ReturnCumulative with dividends-98.9%+73.9%+13.2%-36.5%
10-Year ReturnCumulative with dividends-99.9%+375.2%+166.4%-84.6%
CAGR (3Y)Annualised 3-year return-44.4%+11.8%+2.3%+49.2%
PGEN leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — LIN and APD each lead in 1 of 2 comparable metrics.

LIN is the less volatile stock with a 0.24 beta — it tends to amplify market swings less than PGEN's 1.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. APD currently trades 96.0% from its 52-week high vs RKDA's 16.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricRKDA logoRKDAArcadia Bioscienc…LIN logoLINLinde plcAPD logoAPDAir Products and …PGEN logoPGENPrecigen, Inc.
Beta (5Y)Sensitivity to S&P 5000.98x0.24x0.45x1.44x
52-Week HighHighest price in past year$6.71$521.28$307.29$5.23
52-Week LowLowest price in past year$1.01$387.78$229.11$1.23
% of 52W HighCurrent price vs 52-week peak+16.4%+94.7%+96.0%+79.3%
RSI (14)Momentum oscillator 0–10042.351.755.062.7
Avg Volume (50D)Average daily shares traded35K2.3M1.2M4.3M
Evenly matched — LIN and APD each lead in 1 of 2 comparable metrics.

Analyst Outlook

APD leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: LIN as "Buy", APD as "Buy", PGEN as "Buy". Consensus price targets imply 44.6% upside for PGEN (target: $6) vs 6.0% for APD (target: $313). For income investors, APD offers the higher dividend yield at 2.41% vs LIN's 1.21%.

MetricRKDA logoRKDAArcadia Bioscienc…LIN logoLINLinde plcAPD logoAPDAir Products and …PGEN logoPGENPrecigen, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$539.71$312.78$6.00
# AnalystsCovering analysts284216
Dividend YieldAnnual dividend ÷ price+1.2%+2.4%
Dividend StreakConsecutive years of raises1629
Dividend / ShareAnnual DPS$6.00$7.11
Buyback YieldShare repurchases ÷ mkt cap0.0%+2.0%0.0%0.0%
APD leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

LIN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PGEN leads in 1 (Total Returns). 2 tied.

Best OverallLinde plc (LIN)Leads 2 of 6 categories
Loading custom metrics...

RKDA vs LIN vs APD vs PGEN: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is RKDA or LIN or APD or PGEN a better buy right now?

For growth investors, Linde plc (LIN) is the stronger pick with 3.

0% revenue growth year-over-year, versus -36. 9% for Precigen, Inc. (PGEN). Linde plc (LIN) offers the better valuation at 33. 8x trailing P/E (27. 7x forward), making it the more compelling value choice. Analysts rate Linde plc (LIN) a "Buy" — based on 28 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — RKDA or LIN or APD or PGEN?

On forward P/E, Air Products and Chemicals, Inc.

is actually cheaper at 22. 5x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — RKDA or LIN or APD or PGEN?

Over the past 5 years, Linde plc (LIN) delivered a total return of +73.

9%, compared to -98. 9% for Arcadia Biosciences, Inc. (RKDA). Over 10 years, the gap is even starker: LIN returned +375. 2% versus RKDA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — RKDA or LIN or APD or PGEN?

By beta (market sensitivity over 5 years), Linde plc (LIN) is the lower-risk stock at 0.

24β versus Precigen, Inc. 's 1. 44β — meaning PGEN is approximately 500% more volatile than LIN relative to the S&P 500. On balance sheet safety, Precigen, Inc. (PGEN) carries a lower debt/equity ratio of 14% versus 106% for Air Products and Chemicals, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — RKDA or LIN or APD or PGEN?

By revenue growth (latest reported year), Linde plc (LIN) is pulling ahead at 3.

0% versus -36. 9% for Precigen, Inc. (PGEN). On earnings-per-share growth, the picture is similar: Arcadia Biosciences, Inc. grew EPS 66. 9% year-over-year, compared to -110. 3% for Air Products and Chemicals, Inc.. Over a 3-year CAGR, LIN leads at 0. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — RKDA or LIN or APD or PGEN?

Linde plc (LIN) is the more profitable company, earning 20.

3% net margin versus -32. 2% for Precigen, Inc. — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LIN leads at 26. 3% versus -34. 4% for PGEN. At the gross margin level — before operating expenses — LIN leads at 43. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is RKDA or LIN or APD or PGEN more undervalued right now?

On forward earnings alone, Air Products and Chemicals, Inc.

(APD) trades at 22. 5x forward P/E versus 27. 7x for Linde plc — 5. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PGEN: 44. 6% to $6. 00.

08

Which pays a better dividend — RKDA or LIN or APD or PGEN?

In this comparison, APD (2.

4% yield), LIN (1. 2% yield) pay a dividend. RKDA, PGEN do not pay a meaningful dividend and should not be held primarily for income.

09

Is RKDA or LIN or APD or PGEN better for a retirement portfolio?

For long-horizon retirement investors, Linde plc (LIN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

24), 1. 2% yield, +375. 2% 10Y return). Both have compounded well over 10 years (LIN: +375. 2%, PGEN: -84. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between RKDA and LIN and APD and PGEN?

These companies operate in different sectors (RKDA (Basic Materials) and LIN (Basic Materials) and APD (Basic Materials) and PGEN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

LIN, APD pay a dividend while RKDA, PGEN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

RKDA

Quality Business

  • Sector: Basic Materials
  • Market Cap > $100B
  • Gross Margin > 21%
Run This Screen
Stocks Like

LIN

Quality Mega-Cap Compounder

  • Sector: Basic Materials
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 12%
Run This Screen
Stocks Like

APD

Income & Dividend Stock

  • Sector: Basic Materials
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 10%
Run This Screen
Stocks Like

PGEN

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 103%
  • Gross Margin > 13%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform RKDA and LIN and APD and PGEN on the metrics below

Revenue Growth>
%
(RKDA: -25.9% · LIN: 8.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.